1167 related articles for article (PubMed ID: 9607572)
21. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
23. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Lotz JP; Pautier P; Selle F; Viens P; Fabbro M; Lokiec F; Viret F; Gligorov J; Gosse B; Provent S; Ribrag V; Micléa JM; Dosquet C; Goetschel A; Cailliot C; Lefèvre G; Genève J; Lhommé C;
Bone Marrow Transplant; 2006 Apr; 37(7):669-75. PubMed ID: 16501591
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
29. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
34. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
[TBL] [Abstract][Full Text] [Related]
36. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
37. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
Kuenen BC; Giaccone G; Ruijter R; Kok A; Schalkwijk C; Hoekman K; Pinedo HM
Clin Cancer Res; 2005 Sep; 11(17):6240-6. PubMed ID: 16144927
[TBL] [Abstract][Full Text] [Related]
38. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
Masuda N; Matsui K; Yamamoto N; Nogami T; Nakagawa K; Negoro S; Takeda K; Takifuji N; Yamada M; Kudoh S; Okuda T; Nemoto S; Ogawa K; Myobudani H; Nihira S; Fukuoka M
Clin Cancer Res; 2000 Jun; 6(6):2288-94. PubMed ID: 10873079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
